These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38714931)

  • 21. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
    Grunebaum MF; Galfalvy HC; Choo TH; Keilp JG; Moitra VK; Parris MS; Marver JE; Burke AK; Milak MS; Sublette ME; Oquendo MA; Mann JJ
    Am J Psychiatry; 2018 Apr; 175(4):327-335. PubMed ID: 29202655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder.
    Jones GH; Vecera CM; Ruiz AC; Wu HE; McInturff SI; Orejarena MJ; Smith KA; Soares JC; Zarate CA; Lane SD; Machado-Vieira R
    J Clin Psychiatry; 2024 Apr; 85(2):. PubMed ID: 38696221
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
    Zheng W; Zhou YL; Wang CY; Lan XF; Ning YP
    J Affect Disord; 2023 Aug; 334():145-151. PubMed ID: 37160235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.
    de la Salle S; Phillips JL; Blier P; Knott V
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110507. PubMed ID: 34971723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
    J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suicidality in treatment resistant depression: perspective for ketamine use.
    Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Słupski J; Włodarczyk A; Górska N; Szarmach J; Szałach ŁP; Wiglusz MS; Krysta K; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):258-260. PubMed ID: 31488737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
    Wilkinson ST; Ballard ED; Bloch MH; Mathew SJ; Murrough JW; Feder A; Sos P; Wang G; Zarate CA; Sanacora G
    Am J Psychiatry; 2018 Feb; 175(2):150-158. PubMed ID: 28969441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
    Price RB; Iosifescu DV; Murrough JW; Chang LC; Al Jurdi RK; Iqbal SZ; Soleimani L; Charney DS; Foulkes AL; Mathew SJ
    Depress Anxiety; 2014 Apr; 31(4):335-43. PubMed ID: 24668760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
    Murrough JW; Soleimani L; DeWilde KE; Collins KA; Lapidus KA; Iacoviello BM; Lener M; Kautz M; Kim J; Stern JB; Price RB; Perez AM; Brallier JW; Rodriguez GJ; Goodman WK; Iosifescu DV; Charney DS
    Psychol Med; 2015 Dec; 45(16):3571-80. PubMed ID: 26266877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder.
    Vande Voort JL; Ballard ED; Luckenbaugh DA; Bernert RA; Richards EM; Niciu MJ; Park LT; Machado-Vieira R; Duncan WC; Zarate CA
    J Clin Psychiatry; 2017; 78(8):1068-1074. PubMed ID: 27929610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketamine as augmentation for the treatment of major depression and suicidal risk in advanced cancer: Case report.
    Rodríguez-Mayoral O; Pérez-Esparza R; Domínguez-Ocadio G; Allende-Pérez S
    Palliat Support Care; 2020 Feb; 18(1):110-112. PubMed ID: 31397251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.
    Ballard ED; Wills K; Lally N; Richards EM; Luckenbaugh DA; Walls T; Ameli R; Niciu MJ; Brutsche NE; Park L; Zarate CA
    J Affect Disord; 2017 Aug; 218():195-200. PubMed ID: 28477497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
    Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
    Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.
    Fan W; Yang H; Sun Y; Zhang J; Li G; Zheng Y; Liu Y
    Oncotarget; 2017 Jan; 8(2):2356-2360. PubMed ID: 27926528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
    Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
    Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.